Lytgobi
Generic name: Futibatinib
Drug class:
Multikinase inhibitors
Usage of Lytgobi
Lytgobi (futibatinib) belongs to a class of medications called kinase inhibitors. Futibatinib works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Lytgobi is used in adults to treat bile duct cancer (cholangiocarcinoma) that has spread (metastatic) or cannot be removed by surgery:
Your doctor will make sure you have the correct tumor type to be treated with Lytgobi.
Lytgobi side effects
Get emergency medical help if you have signs of an allergic reaction to Lytgobi: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Lytgobi may cause serious side effects. Call your doctor at once if you have:
Common Lytgobi side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Lytgobi
To make sure Lytgobi is safe for you, tell your doctor if you have:
Futibatinib can harm an unborn baby if the mother or the father is using this medicine.
Do not breastfeed while using this medicine, and for at least 1 week after your last dose.
Relate drugs
- Afatinib
- Alecensa
- Alectinib
- Alunbrig
- Avapritinib
- Ayvakit
- Cobimetinib
- Cotellic
- Crizotinib
- Balversa
- Binimetinib
- Braftovi
- Brigatinib
- Capmatinib
- Ceritinib
- Dabrafenib
- Deucravacitinib
- Encorafenib
- Entrectinib
- Erdafitinib
- Fedratinib
- Futibatinib
- Gavreto
- Gilotrif
- Gilteritinib
- Infigratinib
- Inrebic
- Jakafi
- Koselugo
- Larotrectinib
- Litfulo
- Lorbrena
- Lorlatinib
- Lytgobi
- Mekinist
- Mektovi
- Midostaurin
- Momelotinib
- Nintedanib
- Ofev
- Ojjaara
- Pacritinib
- Pemazyre
- Pemigatinib
- Pexidartinib
- Pralsetinib
- Qinlock
- Retevmo
- Ripretinib
- Ritlecitinib
- Rozlytrek
- Ruxolitinib
- Ruxolitinib (Oral)
- Rydapt
- Selpercatinib
- Selumetinib
- Sotyktu
- Tabrecta
- Tafinlar
- Tepmetko
- Tepotinib
- Trametinib
- Truseltiq
- Turalio
- Ukoniq
- Umbralisib
- Vemurafenib
- Vitrakvi
- Vonjo
- Xalkori
- Xospata
- Zelboraf
- Zykadia
How to use Lytgobi
Usual Adult Dose for Cholangiocarcinoma of biliary tract:
Usual dose: 20 mg (five 4 mg tablets) taken orally once daily Comments: -Confirm the presence of an FGFR2 gene fusion or other rearrangement prior to initiation of treatment. -Treatment to be continued until disease progression or unacceptable toxicity occurs. Use: Patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
Warnings
You should not use Lytgobi if you are allergic to futibatinib, any other medications, or any of the ingredients in Lytgobi tablets.
Tell your doctor and pharmacist what prescription and non-prescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take while taking Lytgobi. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
Tell your doctor if you have diabetes, anemia, history of bleeding disorder, or if you have or ever had kidney or liver problems.
Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.
What other drugs will affect Lytgobi
Tell your doctor about all your other medicines, especially:
This list is not complete. Other drugs may interact with futibatinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions